Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 70

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 70
---
 it, and potential
competitors may be effective in onboarding these or other high-quality fertility specialists to create a similarly high-quality network.
There may be additional shifts in the fertility specialty provider space as the fertility market matures, and high-quality fertility specialists
may become more demanding in re-negotiating to remain in its network. Its ability to develop and maintain satisfactory relationships with
high-quality fertility specialists also may be negatively impacted by other factors not associated with it, such as regulatory changes
impacting providers or consolidation activity among hospitals, physician groups and healthcare providers. In addition, certain organizations
of physicians, such as practice management companies (which group together physician practices for administrative efficiency), may change
the way in which healthcare providers do business with it and may compete directly with it, which could adversely affect its business,
financial condition and results of operations. NewGenIvf intends to grant, and may continue to grant, options and other types of awards,
which may result in increased share-based compensation expenses.

NewGenIvf’s Share Incentive
Award will allow NewGenIvf to enhance its ability to attract and retain exceptionally qualified individuals and agents and to encourage
them to acquire a proprietary interest in the company’s growth and performance. Competition for highly skilled personnel and agents
is often intense and NewGenIvf may incur significant costs or may not be successful in attracting, integrating, or retaining qualified
personnel and agents to fulfill NewGenIvf’s current or future needs. NewGenIvf believes that the granting of share-based awards
is of significant importance to NewGenIvf’s ability to attract and retain agents, key personnel and employees, and NewGenIvf will
continue to grant share-based awards in the future. In addition, NewGenIvf may, with the approval of its Compensation Committee and the
Board, revise the terms of, and increase the size of, its share incentive plan, to ensure that it is able to attract and retain agents,
key personnel and employees. On March 31, 2025, NewGenIvf’s Board approved certain amendments to its Share Incentive Plan, including
the increase of the size of the share incentive plan to 20% of the outstanding shares of the Company from time to time. As a result, NewGenIvf’s
expenses associated with share-based compensation may increase, which may have an adverse effect on NewGenIvf’s results of operations.
The amended share incentive plan is available as Exhibit 4.32.

Meanwhile, the